BackNeuroPace Overview
NeuroPace Inc

NeuroPace Target Price

Analysts' average 12-month price target for NeuroPace is $21.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.75

Average Target Price

$21.0042.4% upside

2 analysts in the last 4 months

High: $22 | Low: $20

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-23Mizuho Securities$2249.2% upsideOpen
2026-05-15H.C. Wainwright$2035.6% upsideOpen
2026-01-27H.C. Wainwright$1928.8% upsideOpen
2025-12-16UBS$2249.2% upsideOpen
2025-12-09UBSPriya Sachdeva$1822% upsideOpen
2025-11-05Leerink PartnersMike Kratky$1928.8% upsideOpen
2025-11-05Cantor FitzgeraldRoss Osborn$168.5% upsideOpen
2024-08-14Wells FargoVik Chopra$151.7% upsideOpen
2024-05-23Lake StreetFrank Takkinen$2035.6% upsideOpen
2024-03-14Wells FargoLarry Biegelsen$2035.6% upsideOpen
2023-11-10Cantor FitzgeraldRoss Osborn$1125.4% downsideOpen
2022-07-15Morgan Stanley$5.562.7% downsideOpen
2022-05-13Morgan Stanley$659.3% downsideOpen

NeuroPace (NPCE) FAQ

NeuroPace's target price stands at $21. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $21 for NPCE implies 42.4% upside versus today's price ($14.75). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how NeuroPace's target price evolved across reporting periods, while the comparison chart places NPCE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. NeuroPace's reading of $21 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.